BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23998688)

  • 1. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Holmäng S; Babjuk M; Fajkovic H; Seitz C; Klatte T; Pycha A; Bachmann A; Scherr DS; Shariat SF
    Eur Urol; 2014 Jan; 65(1):201-9. PubMed ID: 23998688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy.
    Rink M; Zabor EC; Furberg H; Xylinas E; Ehdaie B; Novara G; Babjuk M; Pycha A; Lotan Y; Trinh QD; Chun FK; Lee RK; Karakiewicz PI; Fisch M; Robinson BD; Scherr DS; Shariat SF
    Eur Urol; 2013 Sep; 64(3):456-64. PubMed ID: 23206854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients.
    Mitra AP; Skinner EC; Schuckman AK; Quinn DI; Dorff TB; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):52.e1-9. PubMed ID: 24239476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does presence of squamous and glandular differentiation in urothelial carcinoma of the bladder at cystectomy portend poor prognosis? An intensive case-control analysis.
    Mitra AP; Bartsch CC; Bartsch G; Miranda G; Skinner EC; Daneshmand S
    Urol Oncol; 2014 Feb; 32(2):117-27. PubMed ID: 23477878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
    Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
    BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Sun M; Fajkovic H; Babjuk M; Bachmann A; Scherr DS; Shariat SF
    Urol Oncol; 2014 Jan; 32(1):49.e7-14. PubMed ID: 24140245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V; Pavone C; Ingargiola GB; Daricello G; Allegro R; Pavone-Macaluso M
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT; Yildirim U; Zorlu F; Ozen H
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of TaG1 non-muscle-invasive bladder cancer.
    Olivier Bosset P; Neuzillet Y; Paoletti X; Molinie V; Botto H; Lebret T
    Urol Oncol; 2015 Jan; 33(1):20.e1-20.e7. PubMed ID: 25282704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of CK20 and Ki-67 immunostaining analysis predicts recurrence, progression, and cancer-specific survival in pT1 urothelial bladder cancer.
    Bertz S; Otto W; Denzinger S; Wieland WF; Burger M; Stöhr R; Link S; Hofstädter F; Hartmann A
    Eur Urol; 2014 Jan; 65(1):218-26. PubMed ID: 22633802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
    Xylinas E; Rink M; Robinson BD; Lotan Y; Babjuk M; Brisuda A; Green DA; Kluth LA; Pycha A; Fradet Y; Faison T; Lee RK; Karakiewicz PI; Zerbib M; Scherr DS; Shariat SF
    Eur J Cancer; 2013 May; 49(8):1889-97. PubMed ID: 23466126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
    Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
    Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative outcomes of primary, recurrent, and progressive high-risk non-muscle-invasive bladder cancer.
    Thomas F; Noon AP; Rubin N; Goepel JR; Catto JW
    Eur Urol; 2013 Jan; 63(1):145-54. PubMed ID: 22985746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of peri-operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Rieken M; El Ghouayel M; Sun M; Karakiewicz PI; Lotan Y; Chun FK; Boorjian SA; Lee RK; Briganti A; Rouprêt M; Fisch M; Scherr DS; Shariat SF
    BJU Int; 2014 Mar; 113(3):393-8. PubMed ID: 24053618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a.
    May M; Bastian PJ; Brookman-May S; Fritsche HM; Tilki D; Otto W; Bolenz C; Gilfrich C; Trojan L; Herrmann E; Moritz R; Tiemann A; Müller SC; Ellinger J; Buchner A; Stief CG; Wieland WF; Höfner T; Hohenfellner M; Haferkamp A; Roigas J; Zacharias M; Nuhn P; Burger M
    Urol Oncol; 2013 Oct; 31(7):1141-7. PubMed ID: 22056404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.